Product Code: IRTNTR70118
Technavio has been monitoring the blepharitis drugs market and it is poised to grow by $ 355.38 mn during 2021-2025 progressing at a CAGR of 5% during the forecast period. Our report on blepharitis drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the increasing use of combination drugs and high-risk factors for blepharitis. In addition, increasing use of combination drugs is anticipated to boost the growth of the market as well.
The blepharitis drugs market analysis includes product segment and geographical landscapes.
Technavio's blepharitis drugs market is segmented as below:
By Product
By Geographical Landscapes
- North America
- Europe
- Asia
- ROW
This study identifies the growing awareness about eye diseases as one of the prime reasons driving the blepharitis drugs market growth during the next few years.
Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on blepharitis drugs market covers the following areas:
- Blepharitis drugs market sizing
- Blepharitis drugs market forecast
- Blepharitis drugs market industry analysis
Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading blepharitis drugs market vendors that include AbbVie Inc., Akorn Inc., Alembic Pharmaceuticals Ltd., Bausch Health Companies Inc., Bayer AG, GlaxoSmithKline Plc, Novartis AG, Pfizer Inc., Sanofi, and Santen Pharmaceutical Co. Ltd.. Also, the blepharitis drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast an accurate market growth.
Table of Contents
Executive Summary
Market Landscape
- Market ecosystem
- Market characteristics
- Value chain analysis
Market Sizing
- Market definition
- Market segment analysis
- Market size 2020
- Market outlook: Forecast for 2020 - 2025
Five Forces Analysis
- Five forces summary
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
Market Segmentation by Product
- Market segments
- Comparison by Product
- Steroids - Market size and forecast 2020-2025
- Antibiotics - Market size and forecast 2020-2025
- Market opportunity by Product
Customer landscape
Geographic Landscape
- Geographic segmentation
- Geographic comparison
- North America - Market size and forecast 2020-2025
- Europe - Market size and forecast 2020-2025
- Asia - Market size and forecast 2020-2025
- ROW - Market size and forecast 2020-2025
- Key leading countries
- Market opportunity by geography
- Market drivers
- Market challenges
- Market trends
Vendor Landscape
- Competitive scenario
- Vendor landscape
- Landscape disruption
Vendor Analysis
- Vendors covered
- Market positioning of vendors
- AbbVie Inc.
- Akorn Inc.
- Alembic Pharmaceuticals Ltd.
- Bausch Health Companies Inc.
- Bayer AG
- GlaxoSmithKline Plc
- Novartis AG
- Pfizer Inc.
- Sanofi
- Santen Pharmaceutical Co. Ltd.
Appendix
- Scope of the report
- Currency conversion rates for US$
- Research methodology
- List of abbreviations
Exhibit
- 1: Key Finding 1
- 2: Key Finding 2
- 3: Key Finding 3
- 4: Key Finding 5
- 5: Key Finding 6
- 6: Key Finding 7
- 7: Key Finding 8
- 8: Parent market
- 9: Market characteristics
- 10: Offerings of vendors included in the market definition
- 11: Market segments
- 12: Global - Market size and forecast 2020 - 2025 ($ million)
- 13: Global market: Year-over-year growth 2020 - 2025 (%)
- 14: Five forces analysis 2020 & 2025
- 15: Bargaining power of buyers
- 16: Bargaining power of suppliers
- 17: Threat of new entrants
- 18: Threat of substitutes
- 19: Threat of rivalry
- 20: Market condition - Five forces 2020
- 21: Product - Market share 2020-2025 (%)
- 22: Comparison by Product
- 23: Steroids - Market size and forecast 2020-2025 ($ million)
- 24: Steroids - Year-over-year growth 2020-2025 (%)
- 25: Antibiotics - Market size and forecast 2020-2025 ($ million)
- 26: Antibiotics - Year-over-year growth 2020-2025 (%)
- 27: Market opportunity by Product
- 28: Customer landscape
- 29: Market share by geography 2020-2025 (%)
- 30: Geographic comparison
- 31: North America - Market size and forecast 2020-2025 ($ million)
- 32: North America - Year-over-year growth 2020-2025 (%)
- 33: Europe - Market size and forecast 2020-2025 ($ million)
- 34: Europe - Year-over-year growth 2020-2025 (%)
- 35: Asia - Market size and forecast 2020-2025 ($ million)
- 36: Asia - Year-over-year growth 2020-2025 (%)
- 37: ROW - Market size and forecast 2020-2025 ($ million)
- 38: ROW - Year-over-year growth 2020-2025 (%)
- 39: Key leading countries
- 40: Market opportunity by geography ($ million)
- 41: Impact of drivers and challenges
- 42: Vendor landscape
- 43: Landscape disruption
- 44: Industry risks
- 45: Vendors covered
- 46: Market positioning of vendors
- 47: AbbVie Inc. - Overview
- 48: AbbVie Inc. - Business segments
- 49: AbbVie Inc. - Key offerings
- 50: AbbVie Inc. - Key customers
- 51: AbbVie Inc. - Segment focus
- 52: Akorn Inc. - Overview
- 53: Akorn Inc. - Product and service
- 54: Akorn Inc. - Key offerings
- 55: Akorn Inc. - Key customers
- 56: Akorn Inc. - Segment focus
- 57: Alembic Pharmaceuticals Ltd. - Overview
- 58: Alembic Pharmaceuticals Ltd. - Product and service
- 59: Alembic Pharmaceuticals Ltd. - Key offerings
- 60: Alembic Pharmaceuticals Ltd. - Key customers
- 61: Alembic Pharmaceuticals Ltd. - Segment focus
- 62: Bausch Health Companies Inc. - Overview
- 63: Bausch Health Companies Inc. - Business segments
- 64: Bausch Health Companies Inc. - Key offerings
- 65: Bausch Health Companies Inc. - Key customers
- 66: Bausch Health Companies Inc. - Segment focus
- 67: Bayer AG - Overview
- 68: Bayer AG - Business segments
- 69: Bayer AG - Key offerings
- 70: Bayer AG - Key customers
- 71: Bayer AG - Segment focus
- 72: GlaxoSmithKline Plc - Overview
- 73: GlaxoSmithKline Plc - Business segments
- 74: GlaxoSmithKline Plc - Key offerings
- 75: GlaxoSmithKline Plc - Key customers
- 76: GlaxoSmithKline Plc - Segment focus
- 77: Novartis AG - Overview
- 78: Novartis AG - Business segments
- 79: Novartis AG - Key offerings
- 80: Novartis AG - Key customers
- 81: Novartis AG - Segment focus
- 82: Pfizer Inc. - Overview
- 83: Pfizer Inc. - Business segments
- 84: Pfizer Inc. - Key offerings
- 85: Pfizer Inc. - Key customers
- 86: Pfizer Inc. - Segment focus
- 87: Sanofi - Overview
- 88: Sanofi - Business segments
- 89: Sanofi - Key offerings
- 90: Sanofi - Key customers
- 91: Sanofi - Segment focus
- 92: Santen Pharmaceutical Co. Ltd. - Overview
- 93: Santen Pharmaceutical Co. Ltd. - Business segments
- 94: Santen Pharmaceutical Co. Ltd. - Key offerings
- 95: Santen Pharmaceutical Co. Ltd. - Key customers
- 96: Santen Pharmaceutical Co. Ltd. - Segment focus
- 97: Currency conversion rates for US$
- 98: Research Methodology
- 99: Validation techniques employed for market sizing
- 100: Information sources
- 101: List of abbreviations
